scholarly journals A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement

2015 ◽  
Vol 54 (21) ◽  
pp. 2741-2743 ◽  
Author(s):  
Takayuki Shiroyama ◽  
Ayako Tanaka ◽  
Motohiro Tamiya ◽  
Masanari Hamaguchi ◽  
Akio Osa ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Rare Case ◽  
Pleomorphic Carcinoma ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma

scholarly journals Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib

2018 ◽  
Vol 46 (8) ◽  
pp. 3491-3497 ◽  
Author(s):  
Liping Lin ◽  
Fuxi Huang ◽  
Fang Chen ◽  
Yan He ◽  
Jiazhu Hu ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Pleomorphic Carcinoma ◽  
Conventional Chemotherapy ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma ◽  
Cell Components ◽  
Resected Tissue ◽  
Epidermal Growth

Pulmonary pleomorphic carcinoma (PPC) is rare, and the response of patients to conventional chemotherapy is very poor. Here we present a patient with anaplastic lymphoma kinase (ALK)-rearranged advanced PPC treated with crizotinib. Computed tomography revealed a mass in the left upper lung of a nonsmoking 60-year-old woman. Pathological findings using resected tissue were consistent with PPC stage 1A, T1bN0M0. Although the patient received adjuvant radiotherapy, the disease relapsed, quickly progressed, and remained PPC according to analysis of biopsied tissue. Although negative for epidermal growth factor receptor mutations, ALK rearrangements were detected in adenocarcinoma and spindle-cell components. The patient received crizotinib therapy and achieved a partial response for 7 months. This case indicates that patients with PPC, particularly those with adenocarcinoma, may harbor an epithelial component with the ALK rearrangement. Although the progression-free survival of patients treated with crizotinib is limited, they may obtain more benefit compared with conventional chemotherapy.

scholarly journals Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

2015 ◽  
Vol 54 (22) ◽  
pp. 2905-2909 ◽  
Author(s):  
Yosuke Kamide ◽  
Kyoichi Kaira ◽  
Takuya Watanabe ◽  
Shiko Kuribayashi ◽  
Atsushi Ozawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Pleomorphic Carcinoma ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma

scholarly journals Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer

2018 ◽  
Vol 11 (3) ◽  
pp. 777-783 ◽  
Author(s):  
Sachi Okawa ◽  
Takuo Shibayama ◽  
Atsushi Shimonishi ◽  
Jun Nishimura ◽  
Taichi Ozeki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Anaplastic Lymphoma Kinase ◽  
Whole Brain Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma ◽  
Brain Radiotherapy ◽  
Nsclc Patients

Although crizotinib shows marked antitumor activity in anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancer (NSCLC) patients, all treated patients ultimately develop resistance to this drug. Isolated central nervous system failure without progression at extracranial sites is a common progression pattern in ALK rearrangement-positive NSCLC patients treated with crizotinib. Here, we report the success of crizotinib combined with whole-brain radiotherapy in an ALK rearrangement-positive NSCLC patient who developed leptomeningeal carcinomatosis and progression of multiple brain metastases. Additionally, we focused on the mechanism involved by examining the plasma and cerebrospinal fluid concentrations of crizotinib in the present case.

scholarly journals Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique

2018 ◽  
Vol 7 (1) ◽  
pp. 22
Author(s):  
Mohanad Ali AlBayyaa ◽  
Ban A. Abdulmajeed
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Gene Rearrangement ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma ◽  
Signal Pattern

Background/Aim: Anaplastic Lymphoma Kinase (ALK) rearrangement has evaluated activity of NSCLC compared with other molecular subtypes (EGFR, KRAS). Many studies demonstrated that patients with ALK rearrangement positive NSCLC have improved with a good response rates and progression (free survival) when treated with either monotherapy or by a combination therapy compared with EGFR-mutated, KRAS/EGFR/ALK wild type or KRAS-mutated. The aim of this study was to detect and study the signal pattern of normal ALK and compare it to that of mutated ALK with gene rearrangement in cases of non-small cell lung cancer and Inflammatory conditions by implementing the CISH technique. In addition to correlate ALK signal pattern with the histopathological type and grade as well as the age and sex of the patients.Materials & Methods: Forty patients with NSCLC and Inflammatory diseases were enrolled in a comparative cross sectional study. The tissue blocks were sectioned on non-charged slides for the preparation of routine H&E staining. Positively charged slides were used for tissue sections prepared for chromogenic in situ hybridization procedure to detect ALK gene.Results: ALK gene signal break apart was detected in (18/20, 90%) of malignant cases; (0/20, 0%) of non-neoplastic lung lesions. There was a significant statistical difference in their distribution, p < 0.05. While There was no significant association between any disease status and sex P value = 1.000NS. The CISH test was 100% sensitive using negative score as a cutoff point and 90.9% specific. The score was divided into three levels that categorized the cases, so there were six cases in score one (1-32%), nine cases in score two (33-67%) and three cases in score three (68-100%).Conclusion: Detection of ALK rearrangement in the early diagnosis of NSCLC is highly sensitive and can save a lot of efforts in planning chemotherapy regimens. Results were very promising in identifying this mutation by a sensitive and highly specific test. The ALK gene rearrangement could be an early mutation and it is needed as an initiating step for the carcinogenesis process. The presence of a double gene mutation, however, could be the cause of a higher-grade cancer.

scholarly journals Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Oncotarget ◽  
2015 ◽  
Vol 6 (27) ◽  
pp. 24320-24332 ◽  
Author(s):  
Jeeyun Lee ◽  
Hee Cheol Kim ◽  
Jung Yong Hong ◽  
Kai Wang ◽  
Sun Young Kim ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Colorectal Adenocarcinoma ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma
Sign in / Sign up

Export Citation Format

Share Document